Sun Pharma gets US nod for leukaemia drug

MUMBAI - Indian drug major Sun Pharmaceuticals Tuesday said it has secured tentative approval from the United States Food and Drugs Administration for the generic version of Gleeven, used to treat chronic myeloid leukaemia.

The drug will be available in two strengths of 100 mg and 400 mg and the market size for them is estimated at nearly $900 million, the pharmaceuticals company said in a filing with the stock exchanges.

The shares of the company were, however, down Rs.13.75, or 0.93 percent, at the Bombay Stock Exchange, and were ruling at Rs.1,463.90 some half-hour into the trading session Monday.